These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Adaptor protein AP-3 produces synaptic vesicles that release at high frequency by recruiting phospholipid flippase ATP8A1. Xu H; Oses-Prieto JA; Khvotchev M; Jain S; Liang J; Burlingame A; Edwards RH Nat Neurosci; 2023 Oct; 26(10):1685-1700. PubMed ID: 37723322 [TBL] [Abstract][Full Text] [Related]
8. Presynaptic regulation of dopamine release: Role of the DAT and VMAT2 transporters. Mulvihill KG Neurochem Int; 2019 Jan; 122():94-105. PubMed ID: 30465801 [TBL] [Abstract][Full Text] [Related]
9. Synaptic Vesicle Recycling Pathway Determines Neurotransmitter Content and Release Properties. Silm K; Yang J; Marcott PF; Asensio CS; Eriksen J; Guthrie DA; Newman AH; Ford CP; Edwards RH Neuron; 2019 May; 102(4):786-800.e5. PubMed ID: 31003725 [TBL] [Abstract][Full Text] [Related]
11. Dopamine Transporter Localization in Medial Forebrain Bundle Axons Indicates Its Long-Range Transport Primarily by Membrane Diffusion with a Limited Contribution of Vesicular Traffic on Retromer-Positive Compartments. Bagalkot TR; Block ER; Bucchin K; Balcita-Pedicino JJ; Calderon M; Sesack SR; Sorkin A J Neurosci; 2021 Jan; 41(2):234-250. PubMed ID: 33234607 [TBL] [Abstract][Full Text] [Related]
12. Genetic deletion of vesicular monoamine transporter-2 (VMAT2) reduces dopamine transporter activity in mesencephalic neurons in primary culture. Yamamoto H; Kamegaya E; Hagino Y; Imai K; Fujikawa A; Tamura K; Enokiya T; Yamamoto T; Takeshima T; Koga H; Uhl GR; Ikeda K; Sora I Neurochem Int; 2007; 51(2-4):237-44. PubMed ID: 17664021 [TBL] [Abstract][Full Text] [Related]
13. [Involvement of vesicular monoamine transporter in attention deficit hyperactivity disorder]. Lorenzo-Sanz G; Sánchez-Herranz A Rev Neurol; 2011 Mar; 52 Suppl 1():S103-8. PubMed ID: 21365590 [TBL] [Abstract][Full Text] [Related]
14. GZ-793A, a lobelane analog, interacts with the vesicular monoamine transporter-2 to inhibit the effect of methamphetamine. Horton DB; Nickell JR; Zheng G; Crooks PA; Dwoskin LP J Neurochem; 2013 Oct; 127(2):177-86. PubMed ID: 23875622 [TBL] [Abstract][Full Text] [Related]
15. Electron microscopic immunolabeling of transporters and receptors identifies transmitter-specific functional sites envisioned in Cajal's neuron. Pickel VM; Garzón M; Mengual E Prog Brain Res; 2002; 136():145-55. PubMed ID: 12143378 [TBL] [Abstract][Full Text] [Related]
16. Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration. Caudle WM; Richardson JR; Wang MZ; Taylor TN; Guillot TS; McCormack AL; Colebrooke RE; Di Monte DA; Emson PC; Miller GW J Neurosci; 2007 Jul; 27(30):8138-48. PubMed ID: 17652604 [TBL] [Abstract][Full Text] [Related]
17. Inverse relationship between the contents of neuromelanin pigment and the vesicular monoamine transporter-2: human midbrain dopamine neurons. Liang CL; Nelson O; Yazdani U; Pasbakhsh P; German DC J Comp Neurol; 2004 May; 473(1):97-106. PubMed ID: 15067721 [TBL] [Abstract][Full Text] [Related]
18. Lobeline displaces [3H]dihydrotetrabenazine binding and releases [3H]dopamine from rat striatal synaptic vesicles: comparison with d-amphetamine. Teng L; Crooks PA; Dwoskin LP J Neurochem; 1998 Jul; 71(1):258-65. PubMed ID: 9648873 [TBL] [Abstract][Full Text] [Related]
19. Protective actions of the vesicular monoamine transporter 2 (VMAT2) in monoaminergic neurons. Guillot TS; Miller GW Mol Neurobiol; 2009 Apr; 39(2):149-70. PubMed ID: 19259829 [TBL] [Abstract][Full Text] [Related]